Vanguard Fiduciary Trust’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$147K Buy
32,688
+218
+0.7% +$1.63K ﹤0.01% 3655
2026
Q1
$341K Buy
+32,470
New +$317K ﹤0.01% 3344

Other funds holding CDLX

Vanguard Fiduciary Trust's CDLX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Cardlytics (CDLX) stake by 0.67% in Q2 2026, buying an estimated $1.63K and bringing the position to 32,688 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #3655.

Vanguard Fiduciary Trust first reported a position in CDLX in Q1 2026 and has held it in 2 quarters since. The position peaked at $341K in Q1 2026. 41 funds tracked by Wall St. Rank hold CDLX as of Q2 2026.

  • Vanguard Fiduciary Trust held 32,688 shares of Cardlytics worth $147K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 218 Cardlytics shares in Q2 2026, an estimated $1.63K.
  • Cardlytics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3655 holding.
  • Vanguard Fiduciary Trust first reported a position in Cardlytics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Cardlytics position peaked at $341K in Q1 2026.
  • 41 funds tracked by Wall St. Rank held Cardlytics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.